
Otonomy OTIC
Quartalsbericht 2022-Q3
hinzugefügt 23.05.2026
Otonomy Zahlungsmittel 2011-2026 | OTIC
Zahlungsmittel Jährlich Otonomy
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 77.4 M | 30.8 M | 25.2 M | 33.6 M | 18.5 M | 24.2 M | 159 M | 140 M | 37.3 M | 4.66 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 159 M | 4.66 M | 55 M |
Zahlungsmittel Vierteljährlich Otonomy
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 40.1 M | 53.1 M | 62.9 M | 77.4 M | 81.8 M | 85.1 M | 51 M | 30.8 M | 54.2 M | 32 M | 31 M | 25.2 M | 16.3 M | 12.1 M | 16.3 M | 33.6 M | 21.4 M | 19 M | 23.2 M | 18.5 M | 16.9 M | 22.3 M | 13.7 M | 24.2 M | 19.8 M | 46.6 M | 244 M | 159 M | 177 M | 190 M | 201 M | 140 M | 165 M | 140 M | 140 M | 37.3 M | 37.3 M | - | - | 4.66 M | - | - | - | 7.66 M | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 244 M | 4.66 M | 65.9 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
261 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
88.9 M | $ 1.66 | 1.22 % | $ 194 M | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
28.9 M | $ 31.65 | 2.59 % | $ 2.1 B | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
7.68 B | $ 93.0 | 0.81 % | $ 22.5 B | ||
|
CRISPR Therapeutics AG
CRSP
|
348 M | $ 53.53 | 3.76 % | $ 4.81 B | ||
|
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
90.6 M | $ 2.76 | 4.15 % | $ 258 M | ||
|
Abcam plc
ABCM
|
89 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.89 M | $ 0.78 | 14.33 % | $ 35.6 M | ||
|
Esperion Therapeutics
ESPR
|
168 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
25.9 M | $ 32.4 | 3.55 % | $ 872 M | ||
|
Affimed N.V.
AFMD
|
38.5 M | - | -34.95 % | $ 21.5 M | ||
|
Forte Biosciences
FBRX
|
77 M | $ 21.47 | -2.14 % | $ 278 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
12.4 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | ||
|
Galectin Therapeutics
GALT
|
17.7 M | $ 2.7 | -3.23 % | $ 173 M | ||
|
Generation Bio Co.
GBIO
|
76.3 M | - | - | $ 344 M | ||
|
IMV
IMV
|
21.2 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
Grifols, S.A.
GRFS
|
980 M | $ 8.05 | 0.5 % | $ 5.47 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | ||
|
Hutchison China MediTech Limited
HCM
|
71.3 M | $ 11.72 | -0.26 % | $ 10.1 B | ||
|
Heron Therapeutics
HRTX
|
28.6 M | $ 0.91 | 3.0 % | $ 152 M | ||
|
ImmuCell Corporation
ICCC
|
3.81 M | $ 10.63 | 1.24 % | $ 95.9 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
3.5 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
47.3 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
1.45 B | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
57.5 M | $ 14.81 | -0.54 % | $ 212 M | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | ||
|
Ionis Pharmaceuticals
IONS
|
372 M | $ 76.49 | 0.55 % | $ 12.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M |